

Components of the Ether-Insoluble Resin Glycoside Fraction from the Seed of *Cuscuta australis*¹

Xiao-Ming Du,[†] Ning-Yi Sun,[†] Masatoshi Nishi,[†] Toshio Kawasaki,[†] Yong-Tian Guo,[‡] and Kazumoto Miyahara*[†]

Faculty of Pharmaceutical Sciences, Setsunan University, 45-1, Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan, and Institute of Medical and Pharmaceutical Sciences Dalian, Chunyangjie 21, Dalian 116013, China

Received November 11, 1998

An ether-insoluble resin glycoside fraction was obtained from the seeds of *Cuscuta australis*. Identification and characterization of alkaline hydrolysis products by means of GC, FABMS, and ¹H, ¹³C, and 2D NMR revealed the material to be composed of three new glycosidic acids, cuscutic acids A₁–A₃ (**1**–**3**); triglycosides with (1*S*)-jalapinic or (1*S*)-convolvulinic acid as the aglycon; and acetic, isobutyric, (2*S*)-2-methylbutyric, tiglic, and (2*R*,3*R*)-nilic acids. The resin glycoside is considered to be a complex mixture of glycosidic ester-type oligomers (up to heptamers) with a core consisting of a number of the above cuscutic acids each acylated with one or two carboxylic acid moieties.


Cuscuta Semen is a well-known Chinese traditional medicine used as a tonic.² The Chinese Pharmacopoeia³ specifies the seeds of *Cuscuta chinensis* Lam (Convolvulaceae) as its origin. However, several species belonging to the same genus, such as *C. australis* and *C. japonica*, are commercialized as substitutes under the same name in the Chinese market.⁴ In a preceding paper, we reported two acylated trisaccharides, cus-1 and cus-2, closely related to the so-called resin glycoside,⁵ and four glycosidic acids along with acetic acid, propionic acid, (2*S*)-2-methylbutyric, tiglic, (2*R*,3*R*)-nilic, (1*S*)-convolvulinic, and (1*S*)-jalapinic acids obtained by alkaline hydrolysis of the ether-insoluble resin glycoside-like fraction of the seeds of *C. chinensis*.⁶ To clarify the relation of the chemical constituents of *C. chinensis* and other members of the *Cuscuta* genus, we examined the resin glycosides of the seeds of *C. australis* and obtained a complex mixture of ether-insoluble resin glycosides with relatively high molecular weights. This paper describes the characterization of several component glycosidic acids and organic acids obtained by alkaline hydrolysis of the ether-insoluble resin glycoside fraction.

Results and Discussion

Powdered seeds of *C. australis* were percolated with Me₂CO at room temperature. The extract was defatted with *n*-hexane, and the residue was partitioned with the mixture CHCl₃–MeOH–H₂O (1:1:1). The lower layer was concentrated and treated with ether. The residue was subjected to LH-20 column chromatography to give an ether-insoluble resin glycoside fraction, 0.15% based on the seeds. The matrix-assisted laser desorption ionization time-of-flight (MALDI TOF) MS showed many peaks around *m/z* 1585, 2406, 3193, 3989, 4793, and 5580, similar to that of *C. chinensis*.⁶ Every effort to isolate individual components was unsuccessful.

Alkaline hydrolysis of the ether-insoluble resin glycoside fraction yielded low molecular weight carboxylic acid and glycosidic acid fractions. The former was methylated with diazomethane, and gas chromatography (GC) revealed the presence of acetic, isobutyric, 2-methylbutyric, tiglic, and

nilic (3-hydroxy-2-methylbutyric) acids. The absolute configurations of 2-methylbutyric and 3-hydroxy-2-methylbutyric acids were determined as 2*S* and 2*R*,3*R*, respectively, by comparison of the specific rotations of their 4-bromophenacyl esters with those obtained from *C. chinensis*.^{5,6} Reversed-phase column chromatography and HPLC of the glycosidic acid fraction gave three new glycosidic acids named cuscutic acids A₁ (**1**), A₂ (**2**), and A₃ (**3**).



Compound **1** was obtained as a white powder, mp 173–176 °C, C₃₄H₆₂O₁₆, from aqueous MeOH. On complete acidic hydrolysis, **1** furnished (1*S*)-jalapinic acid⁷ (11*S*-hydroxyhexadecanoic acid), D-fucose, D-glucose, and L-rhamnose in a ratio of about 1:1:1. The absolute configurations of the hydroxy fatty acids and the sugars were determined by the Mosher method⁷ and the Hara method,⁸ respectively. The negative ion FABMS of **1** showed a quasi molecular ion peak at *m/z* 725 [M – H][–] along with fragment peaks at *m/z* 579 [725 – 146 (C₆H₁₀O₄, methylpentose unit)][–], 417 [579 – 162 (C₆H₁₀O₅, hexose unit)][–], and 271 [417 – 146, jalapinic acid – H][–], indicating that **1** was a glycoside composed of jalapinic acid, fucose, glucose, and rhamnose (1:1:1) and that the sequence of the sugar moiety was either rhamnosyl–glucosyl–fucose or fucosyl–glucosyl–rhamnose.

* To whom correspondence should be addressed. Tel.: + 720-66-3138. Fax: +720-66-3139, E-mail: miyahara@pharm.setsunan.ac.jp.

[†] Faculty of Pharmaceutical Sciences.

[‡] Institute of Medical and Pharmaceutical Sciences.

Table 1. NMR Spectra Data for Compounds **1**, **2a**, and **3** (Pyridine-*d*₅)^a

	1		2a		3	
	¹ H ^b	¹³ C ^c	¹ H ^b	¹³ C ^c	¹ H ^b	¹³ C ^c
Fuc-1	4.76 d (7.7)	102.6	4.78 d (7.7)			
2	4.49 dd (7.7, 9.3)	78.2	4.47 dd (7.7, 9.1)			
3	4.33 dd (9.3, 3.6)	76.2	5.31 dd (9.1, 3.3)			
4	3.81 br d (3.6)	72.6	5.67 dd (3.3, 1.0)			
5	3.71 br q (6.4)	71.0	3.92 dq (1.0, 6.3)			
6	1.46 d (3H, 6.4)	17.2	1.23 d (3H, 6.3)			
Glc-1					4.99 d (7.8)	102.5
2					4.33 dd (7.8, 9.3)	80.0
3					4.51 dd (9.3, 9.3)	79.4
4					4.12 dd (9.3, 9.3)	72.0
5					3.90 ddd (9.3, 5.3, 2.7)	77.9
6					4.32 dd (5.3, 11.5)	62.8
					4.46 dd (11.5, 2.7)	
Glc'-1	5.63 d (7.7)	102.3	5.32 d (7.7)		5.81 d (7.7)	102.2
2	4.22 dd (7.7, 9.3)	78.4	4.09 dd (7.7, 9.5)		4.26 dd (7.7, 9.4)	79.8
3	4.16 dd (9.3, 9.3)	79.3	5.82 dd (9.5, 9.5)		4.23 dd (9.4, 9.4)	79.3
4	4.03 dd (9.3, 9.3)	72.6	5.41 dd (9.5, 9.5)		4.08 dd (9.4, 9.4)	72.6
5	3.62 ddd (9.3, 5.2, 3.2)	77.1	4.04 ddd (9.5, 4.3, 2.6)		3.85 ddd (9.4, 5.2, 2.7)	77.5
6	4.17 dd (5.2, 11.7)	63.2	4.58 dd (4.3, 12.1)		4.27 dd (5.2, 11.5)	63.3
	4.26 dd (11.7, 3.2)		4.33 dd (12.1, 2.6)		4.44 dd (11.5, 2.7)	
Rha-1	6.32 d (1.5)	101.9	5.42 d (1.6)		6.32 dd (1.5)	102.2
2	4.73 dd (1.5, 3.2)	72.4	5.60 dd (1.6, 3.2)		4.74 dd (1.5, 3.2)	72.3
3	4.72 dd (3.2, 8.9)	72.7	5.66 dd (3.2, 10.3)		4.67 dd (3.2, 9.1)	72.6
4	4.30 dd (8.9, 8.9)	74.4	5.62 dd (10.3, 10.3)		4.30 dd (9.1, 9.1)	74.4
5	4.99 dq (8.9, 6.1)	69.6	4.60 dq (10.3, 6.3)		5.00 dq (9.1, 6.2)	69.7
6	1.82 d (3H, 6.1)	19.0	1.61 d (3H, 6.3)		1.79 d (3H, 6.2)	19.0
Ag-1		176.1				176.4
2	2.50 t (2H, 7.5)	34.9	2.56 t (2H, 7.4)		2.51 t (2H, 7.5)	35.1
11	3.89 m	80.2	3.84 m		3.96 m	80.5
14			0.92 t (3H, 7.3)		0.87 t (3H, 7.5)	14.5
16	0.83 t (3H, 7.5)	14.2				

^a All assignments are based on ¹H-¹H COSY, NOESY, and ¹H-¹³C COSY spectra. Coupling constants (*J*) are in parentheses. Fuc, fucopyranosyl; Glc, glucopyranosyl; Rha, rhamnopyranosyl; Ag, aglycon (jalapinic or convolvulinic acid); br, broad. ^b At 600 MHz. ^c At 150 MHz.

The ¹H and ¹³C NMR signals of **1** were assigned with the aid of COSY, NOESY, and C-H COSY experiments. The spectra included signals for a terminal methyl and equivalent methylene groups ascribable to the aglycon (jalapinic acid) at δ_{H} 0.83 (3H, t)/ δ_{C} 14.2 and δ_{H} 2.50 (2H, t)/ δ_{C} 34.9. The component sugar moieties were determined to be β -fucopyranosyl (Fuc) in ⁴C₁, β -glucopyranosyl (Glc) in ⁴C₁ and α -rhamnopyranosyl (Rha) in ¹C₄ conformation, respectively, by vicinal ¹H-¹H coupling constants (Table 1). Their modes of the glycosidic linkage were supported by ¹J_{C1-H1}⁹ (Fuc, 156 Hz; Glc, 158 Hz; Rha, 171 Hz).

Comparing the ¹³C NMR chemical shifts of **1** and the methyl pyranosides in the literature,¹⁰ glycosylation shifts were observed at C-2 of Fuc (+6.2 ppm) and C-2 of Glc (+3.5 ppm) (Table 1). The NOESY spectrum of **1** revealed cross peaks between H-1 of Rha/H-2 of Glc, H-1 of Glc/H-2 of Fuc, and H-1 of Fuc/H-11 of the aglycon. These data implied that the linkages of **1** are Rha-(1 \rightarrow 2)-Glc-(1 \rightarrow 2)-Fuc-(1 \rightarrow 11)-aglycon. Accordingly, **1** was characterized as (11*S*)-jalapinic acid 11-*O*- α -L-rhamnopyranosyl-(1 \rightarrow 2)-*O*- β -D-glucopyranosyl-(1 \rightarrow 2)- β -D-fucopyranoside. The structure corresponds to that of the glycosidic acid moiety of tricolorin G and unit A of tricolorin H of *Ipomoea tricolor*.¹¹

Compound **2**, mp 178–180 °C, C₃₂H₅₈O₁₆, gave (11*S*)-convolvulinic acid, D-fucose, D-glucose, and L-rhamnose on acidic hydrolysis. The negative FABMS showed the [M - H]⁻ ion peak at *m/z* 697 along with fragment peaks at *m/z* 551, 389, and 243, all of which were 28 mass units (C₂H₄) less than those of **1**, thus **2** is composed of 1 unit each of convolvulinic acid⁷ (11-hydroxytetradecanoic acid), D-fucose, D-glucose, and L-rhamnose, with the sugar moiety similar to that of compound **1**. The ¹H and ¹³C NMR spectra of **2** were superimposable on those of **1** except for signals

due to the convolvulinic acid moiety. Moreover, comparing the ¹H NMR spectral data between **2** and its peracetate (**2a**), the signals at 3-H and 4-H of fucose, and those of glucose, were shifted downfield by 0.98, 1.86, 1.66, and 1.38 ppm, respectively, whereas those of 2-H were shifted upfield by 0.02 and 0.13 ppm, respectively. Therefore, the sugar moieties of **1** and **2** are identical, including their conformation. Thus, **2** is (11*S*)-convolvulinic acid 11-*O*- α -L-rhamnopyranosyl-(1 \rightarrow 2)-*O*- β -D-glucopyranosyl-(1 \rightarrow 2)- β -D-fucopyranoside.

Compound **3**, a white powder, mp 185–188 °C, C₃₂H₅₈O₁₇, afforded, on acidic hydrolysis, (11*S*)-convolvulinic acid, and D-glucose and L-rhamnose in the ratio 2:1. Its negative FABMS showed the [M - H]⁻ ion peak at *m/z* 713 and fragment peaks at *m/z* 567 [713 - 146]⁻, 405 [567 - 162]⁻ and 243 [405 - 162]⁻, so that **3** was suggested to be a triglycoside consisting of 1 mol each of convolvulinic acid and rhamnose, and 2 mol of glucose, in which the inner D-fucose of **2** is substituted by D-glucose in **3**. The NOESY and ¹³C NMR spectra demonstrated that the glycosidic linkages are at the 2-OH of Glc, 2-OH of Glc', and the 11-OH of the convolvulinic acid moiety, and further, the glycosidic linkages of Rha, Glc, and Glc' were determined to be α in ¹C₄, β in ⁴C₁, and β in ⁴C₁, respectively, the same as for **1** (Table 1). Thus, the structure of **3** was defined as (11*S*)-convolvulinic acid 11-*O*- α -L-rhamnopyranosyl-(1 \rightarrow 2)-*O*- β -D-glucopyranosyl-(1 \rightarrow 2)- β -D-glucopyranoside.

The glycosidic acids from *C. australis* are all triglycosides, although those from *C. chinensis*, cuscutic acids A–D, are tetraglycosides. Neither free jalapinic nor convolvulinic acids, nor the trisaccharides obtained as components in the alkaline hydrolysate of the resin from *C. chinensis*,^{5,6} were found in *C. australis*. Taking the

features of the MALDI-TOF MS into account, the resin glycoside from this plant is considered to be a complex mixture of ester-type oligomers (up to heptamer), which consist of a variety of glycosidic acids each acylated with one or two organic acids such as acetic, isobutyric, (2*S*)-2-methylbutyric, tiglic, and (2*R*,3*R*)-nilic acids.

Experimental Section

General Experimental Procedures. Melting points were determined on a Yanaco MP-S3 apparatus and are uncorrected. Specific rotations were determined on a JASCO DIP-140 polarimeter at 17 °C. ¹H, ¹³C, and 2D NMR spectra were recorded on a GE Omega 600 spectrometer at 26 °C using pyridine-*d*₅ as a solvent unless otherwise cited. EIMS and FABMS were measured on a JEOL JMS DX-300 spectrometer, and MALDI TOF MS was performed on a Perceptive Voyager Elite spectrometer. Triethanolamine was used as a matrix for the FABMS measurements. Analytical GC was carried out on a Shimadzu GC-8A gas chromatograph for organic and hydroxy fatty acids and on a Hitachi G-3000 gas chromatograph for sugars, equipped with FID.

Plant Material. The seeds of *C. australis*, whose host plant was *Sesamum indicum* DC., were collected in Inner Mongolia, China, in August 1992, and verified by Mr. Daixian Chen, Institute for Drug Control of Dalian, China. The voucher specimen (CONV-022) has been deposited in the herbarium of the Botanical Garden of the Faculty of Pharmaceutical Sciences, Setsunan University.

Extraction and Purification of the Ether-Insoluble Resin Glycoside Fraction. Powdered seeds of *C. australis* (1.2 kg) were percolated with Me₂CO (7 L) at room temperatures and the extract was evaporated under reduced pressure to afford a brown syrup (65 g). This was defatted with *n*-hexane (100 mL × 3), and the residue (10.8 g) was partitioned with CHCl₃-MeOH-H₂O (1:1:1, 300 mL). Concentration of the lower layer furnished a powder (2.32 g), which was treated with ether (25 mL × 2). The residue (2.12 g) was subjected to Sephadex LH-20 column chromatography (80 × 3.5 cm i.d., MeOH) to provide an ether-insoluble resin glycoside fraction (1.77 g, 0.15%), as a white powder, MALDI TOF MS (matrix; sinapic acid) major peaks at *m/z* 1585, 2406, 3193, 3989, 4793, and 5580.

Alkaline Hydrolysis of the Ether-Insoluble Fraction. The ether-insoluble resin glycoside fraction (1.5 g) was dissolved in 3% KOH (10 mL) and allowed to stand at 37 °C for 5 h. The mixture was adjusted to pH 4 with 1M HCl, and then extracted with Et₂O (5 mL × 3). The combined Et₂O layers were washed with H₂O and dried over Na₂SO₄. Evaporation of the Et₂O gave an oil (organic acid fraction, 137 mg). The H₂O layer was chromatographed over Mitsubishi chemical CHP 20P (25 × 5 cm i.d., H₂O → MeOH), and the MeOH eluate gave a white powder (glycosidic acid fraction, 1.18 g).

Identification of Organic Acids. The organic-acid fraction (1 mg) was examined by GC [condition 1: 2 m × 3.2 mm i.d. packed with Unisol 30T (5%); isothermal 110 °C; N₂ at 0.5 kg cm⁻²], *t*_R (min) 2.13 (acetic acid), 3.59 (isobutyric acid), 5.97 (2-methylbutyric acid), 14.12 (tiglic acid). The organic-acid fraction (1 mg) was methylated with CH₂N₂ in the usual way and analyzed by GC under the same conditions as above except for column temperature: 100 °C, *R*_t (min) 7.59 (methyl nilate).

A solution of the organic-acid fraction (130 mg) in dry Me₂CO (5 mL) was neutralized with triethylamine. 4-Bromophenacyl bromide (110 mg) was added, and the mixture was allowed to stand at room temperature for 1 h. After removal of the solvent, the residue was diluted with H₂O (5 mL) and extracted with Et₂O (5 mL × 3). The combined Et₂O layer was concentrated and then chromatographed over Si gel using *n*-hexane-EtOAc (10:1) → EtOAc to afford 4-bromophenacyl (2*S*)-2-methylbutyrate (8.5 mg): colorless needles, mp 41–42 °C, [α]_D +9.8° (c 0.8, CHCl₃) and 4-bromophenacyl (2*R*,3*R*)-nilate (11.7 mg), colorless needles, mp 70–72 °C, [α]_D¹⁷ -14.3° (c 1.1, CHCl₃). These were identical in all respects to known standards (¹H NMR, EIMS, and specific rotation).⁶

Isolation of Cuscutic Acids A₁ (1), A₂ (2), and A₃ (3). The glycosidic acid fraction (100 mg) was purified over Nacalai Tesque Cosmosil 75 C18-opn (28 × 2 cm i.d., 75% MeOH) and then subjected to HPLC on GL Sciences Inertsil ODS (250 × 20 mm i.d., 83% MeOH) to afford **1** (11 mg), **2** (61 mg), and **3** (15 mg), respectively.

Cuscutic Acid A₁ (1): obtained as a white powder (MeOH-H₂O); mp 173–176 °C, [α]_D¹⁷ -38.7° (c 1.1, MeOH); negative ion FABMS *m/z* 725, 579, 417, 271; *anal.* C 56.09%, H 8.76%, calcd for C₃₄H₆₂O₁₆, C 56.18%, H 8.60%; ¹H and ¹³C NMR δ, see Table 1; ¹J_{C1-H1} Hz 156 (Fuc), 158 (Glc), 171 (Rha).

Cuscutic Acid A₂ (2): obtained as a white powder (MeOH-H₂O), mp 178–180 °C; [α]_D¹⁷ -41.5° (c 5.5, MeOH); negative ion FABMS *m/z* 697, 551, 389, 243; *anal.* C 54.89%, H 8.25%, calcd for C₃₂H₅₈O₁₆, C 55.00%, H 8.37%; ¹H and ¹³C NMR δ, see Table 1; ¹J_{C1-H1} Hz 156 (Fuc), 157 (Glc), 172 (Rha).

Cuscutic Acid A₃ (3): obtained as a white powder (MeOH-H₂O), mp 185–188 °C; [α]_D¹⁷ -79.2° (c 0.95, MeOH); negative ion FABMS *m/z* 713, 567, 405, 243; *anal.* C 53.63%, H 8.29%, calcd for C₃₂H₅₈O₁₇, C 53.77%, H 8.18%; ¹H and ¹³C NMR δ, see Table 1; ¹J_{C1-H1} Hz 157 (Glc), 159 (Glc'), 171 (Rha).

Acidic Hydrolysis of 1, 2, and 3. Compounds **1** (9 mg), **2** (11 mg), and **3** (10 mg) were separately dissolved in 5% H₂SO₄ (2 mL) and heated at 95 °C for 1 h. The reaction mixture in each case was diluted with H₂O (2 mL), then extracted with Et₂O. The Et₂O layer was treated with CH₂N₂, then the product was examined by GC [condition 2: column, 2 m × 3.2 mm i.d. packed with silicone OV-17 (2%); N₂ at 1 kg cm⁻²; isothermal 240 °C; *t*_R (min) 4.53 (methyl convolvulinolate) for **2** and **3**, 7.23 (methyl jalapinolate) for **1**]. A mixture of methyl jalapinolate (2 mg from **1**), (-)-1-methoxy-1-trifluoromethylphenylacetyl (MTPA) chloride (4 mg), dicyclohexylcarbodiimide (6 mg), and 4-(dimethylamino)pyridine (2 mg) in Et₂O (1.5 mL) was stirred at room temperature overnight. The solvent was removed under a stream of N₂, and the residue was purified over a Si gel column chromatography using *n*-hexane-Et₂O (10:1) to give the (-)-MTPA ester (3 mg) as a colorless oil; ¹H NMR (600 MHz, CDCl₃) δ 0.84 (3H, t, *J* = 6.9 Hz, H₃-16), 2.30 (2H, t, *J* = 7.5 Hz, H₂-2), 3.56 (3H, q, *J* = 1.2 Hz, OCH₃), 3.67 (3H, s, COOCH₃), 5.08 (1H, tt, *J* = 5.5, 6.7 Hz, H-13). These data were identical with those of an authentic (-)-MTPA ester of methyl (11*S*)-jalapinolate [cf. (+)-MTPA ester δ 0.88 (3H, t, *J* = 6.9 Hz, H₃-16)]. In the same manner as above, the methyl convolvulinolate (each 2 mg from **2** and **3**) was transformed to the (-)-MTPA ester to afford a colorless oil, respectively: ¹H NMR (600 MHz, CDCl₃) δ 0.85 (3H, t, *J* = 7.3 Hz, H₃-14), 2.30 (2H, t, *J* = 7.5 Hz, H₂-2), 3.55 (3H, q, *J* = 1.2 Hz, OCH₃), 3.67 (3H, s, COOCH₃), 5.10 (1H, tt, *J* = 5.3, 7.0 Hz, H-11). The ¹H NMR in each case was superimposable on that of an authentic sample of the (-)-MTPA ester of methyl (11*S*)-convolvulinolate [cf. (+)-MTPA ester δ 0.92 (3H, t, *J* = 6.9 Hz, H₃-14)].

Each aqueous layer was neutralized with Ba(OH)₂, and the precipitates were filtered off. The filtrate was concentrated, and the residue was subjected to LH-20 column chromatography (MeOH) to afford a sugar mixture as a syrup (5 mg from **1**, 6 mg from **2**, and 5 mg from **3**). The samples were analyzed by GC according to the method of Hara et al.⁸ (condition 3: WCOT, GL Sciences OV-17, 50 m × 0.25 mm i.d.; isothermal 220 °C; He at 1.5 kg cm⁻²); *t*_R (min) 19.18 (L-rhamnose), 19.77 (D-fucose), and 26.99 (D-glucose) from **1** and **2** in a ratio of ca. 1:1:1, respectively, and 19.19 (L-rhamnose) and 27.01 (D-glucose) from **3** (ca. 1:2).

Acetylation of 2. A solution of **2** (20 mg) in Ac₂O-pyridine (1:1) was heated at 50 °C, for 2 h. The mixture was evaporated under an N₂ stream, and the residue was purified over Si gel using *n*-hexane-Me₂CO (2:1) to give a white powder (**2a**, 28 mg). EIMS *m/z* 791, 561, 289, 273. ¹H NMR δ, see Table 1.

Acknowledgment. The authors are indebted to Dr. Naoki Noda of this faculty for helpful discussions and to Dr. Yasuhiro Itagaki and Dr. Hideo Naoki of Suntory Institute for Bioorganic Research for measurements of MALDI TOF MS.

References and Notes

- (1) Part XXVII in the series "Resin Glycosides". Part XXVI, see Du et al.⁶
- (2) Jiangsu New Medicinal College. *Dictionary of the Traditional Chinese Medicines*, Shanghai Scientific Technologic Publishing House: Shanghai, China, 1985; pp 2006–2008.
- (3) Pharmacopoeia Committee of the Health Ministry of the People's Republic of China. *Pharmacopoeia of People's Republic of China*; Guangdong Scientific Technologic Publishing House: Guangdong, China, 1995; p 269.
- (4) Guo, C.; Zhang, Z.; Zheng, H.; Su, Z.; Li, C. *China J. Chin. Mater. Med.* **1990**, *15*, 138–145.
- (5) Miyahara, K.; Du, X.-M.; Watanabe, M.; Sugimura, C.; Yahara, S.; Nohara, T. *Chem. Pharm. Bull. (Tokyo)* **1996**, *44*, 481–485.
- (6) Du, X.-M.; Kohinata, K.; Kawasaki, T.; Guo Y.-T.; Miyahara, K. *Phytochemistry* **1998**, *48*, 843–850.
- (7) Ono, M.; Yamada, F.; Noda, N.; Kawasaki, T.; Miyahara, K. *Chem. Pharm. Bull.* **1993**, *41*, 1023–1026.
- (8) Hara, S.; Okabe, H.; Mihashi, K. *Chem. Pharm. Bull.* **1987**, *35*, 501–506.
- (9) Bock, K.; Pedersen, C. *J. Chem. Soc., Perkin Trans. 2* **1974**, 293–297.
- (10) Tanaka, O. *Yakugaku Zasshi* **1985**, *105*, 323–351.
- (11) Bah, M.; Pedera-Miranda, R. *Tetrahedron* **1997**, *53*, 9007–9022.

NP980506J